An 8-week, Open-Label Clinical Trial of the Efficacy and Safety of Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

Trial Profile

An 8-week, Open-Label Clinical Trial of the Efficacy and Safety of Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

Withdrawn prior to enrolment
Phase of Trial: Phase 0

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 18 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 04 Feb 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top